Perfromance Wealth Partners LLC Has $219,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Perfromance Wealth Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,256 shares of the biopharmaceutical company’s stock after selling 693 shares during the quarter. Perfromance Wealth Partners LLC’s holdings in Pfizer were worth $219,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Thrivent Financial for Lutherans boosted its holdings in Pfizer by 2.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company’s stock valued at $20,684,000 after purchasing an additional 20,140 shares during the period. ProShare Advisors LLC lifted its holdings in shares of Pfizer by 7.3% during the 2nd quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company’s stock worth $23,661,000 after acquiring an additional 57,825 shares during the period. Providence Capital Advisors LLC lifted its holdings in shares of Pfizer by 1.7% during the 2nd quarter. Providence Capital Advisors LLC now owns 113,143 shares of the biopharmaceutical company’s stock worth $3,166,000 after acquiring an additional 1,855 shares during the period. Cheviot Value Management LLC lifted its holdings in shares of Pfizer by 5.5% during the 2nd quarter. Cheviot Value Management LLC now owns 427,539 shares of the biopharmaceutical company’s stock worth $11,963,000 after acquiring an additional 22,112 shares during the period. Finally, Samlyn Capital LLC lifted its holdings in shares of Pfizer by 41.8% during the 2nd quarter. Samlyn Capital LLC now owns 4,906,703 shares of the biopharmaceutical company’s stock worth $137,290,000 after acquiring an additional 1,446,582 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In related news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Price Performance

PFE stock opened at $26.63 on Wednesday. The firm has a market cap of $150.89 billion, a price-to-earnings ratio of 35.98, a PEG ratio of 0.63 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company’s fifty day simple moving average is $26.08 and its 200 day simple moving average is $27.98.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) earnings per share. On average, analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.46%. Pfizer’s payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.